Nina Ressing
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Exploration of Fluorinated Peptoid-Based Histone Deacetylase Inhibitors as Dual-Stage Antiplasmodial Agents.
Journal: Archiv der Pharmazie
Published: October 29, 2024
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6.
Journal: Journal of medicinal chemistry
Published: October 02, 2023
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.
Journal: Journal of medicinal chemistry
Published: November 09, 2022
The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
Journal: Anticancer research
Published: September 27, 2021
Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
Journal: Anticancer research
Published: April 19, 2021
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Journal: Journal of medicinal chemistry
Published: August 18, 2020
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
Journal: Journal of medicinal chemistry
Published: October 27, 2018
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.
Journal: MedChemComm
Published: September 10, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026